News

Ophthalmology Times9h
Nicox completes phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension
Nicox completed the Denali Phase 3 trial for NCX 470, targeting open-angle glaucoma and ocular hypertension. NCX 470 combines ...
Optometry Advisor8h
Semaglutide-Associated NAION Likelihood Higher When Combined With Other Risks
NAION risk is most significant within the first 12 months of beginning semaglutide, and is highest in patients with additional risk factors.